Učitavanje...
An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer
INTRODUCTION: Non-small cell lung cancer (NSCLC) patients with ROS1 chromosomal rearrangements benefit from treatment with the ROS1 inhibitor crizotinib. Limited data exist on the spectrum of resistance mechanisms in ROS1+ NSCLC. To delineate mechanisms of acquired resistance, we analyzed tumor samp...
Spremljeno u:
| Izdano u: | J Thorac Oncol |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4961521/ https://ncbi.nlm.nih.gov/pubmed/27068398 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2016.04.001 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|